About Urotronic
Urotronic is a company based in Plymouth (United States) founded in 2015 was acquired by Laborie Medical in September 2023. Urotronic has raised $47.05 million across 4 funding rounds from investors including Laborie Medical, Legend Capital and CD Capital. Urotronic offers products and services including Optilume BPH Catheter System, Optilume Urethral Drug Coated Balloon, alpHaONE Wireless pH Capsule, and NXT Family of Urodynamics Systems. Urotronic operates in a competitive market with competitors including Neotract, Butterfly Medical, Zenflow, Rivermark and ProVerum Medical, among others.
- Headquarter Plymouth, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Urotronic Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$47.05 M (USD)
in 4 rounds
-
Latest Funding Round
$954.36 K (USD), Series C
Oct 20, 2020
-
Investors
Laborie Medical
& 3 more
-
Employee Count
Not available
-
Acquired by
Laborie Medical
(Sep 06, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Urotronic
Urotronic offers a comprehensive portfolio of products and services, including Optilume BPH Catheter System, Optilume Urethral Drug Coated Balloon, alpHaONE Wireless pH Capsule, and NXT Family of Urodynamics Systems.
Device for treating benign prostatic hyperplasia.
Balloon for anterior urethral stricture therapy.
System for wireless reflux monitoring.
Tools for assessing urinary function.
People of Urotronic
Unlock access to complete
Funding Insights of Urotronic
Urotronic has successfully raised a total of $47.05M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $954.36 thousand completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Urotronic
Urotronic has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Laborie Medical, Legend Capital and CD Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture Capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Healthcare venture capital investments are managed by HM Venture Partners.
|
Locked | Locked | Locked |
Investor details for Urotronic
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Urotronic
Investment portfolio details for Urotronic
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Urotronic
Detailed financials for Urotronic
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Urotronic Comparisons
Peer comparison for Urotronic
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Urotronic
Urotronic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neotract, Butterfly Medical, Zenflow, Rivermark and ProVerum Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Minimally invasive devices in urology
|
|
| Locked | Locked | Locked |
Developer of an implantable device for the treatment of benign prostatic hyperplasia (BPH)
|
|
| Locked | Locked | Locked |
A device is developed to treat urinary obstruction from BPH.
|
|
| Locked | Locked | Locked |
Medical device for benign prostatic hyperplasia treatment is developed.
|
|
| Locked | Locked | Locked |
Developer of a minimally-invasive medical device for benign prostatic hyperplasia
|
Detailed competitors of Urotronic
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Urotronic
Complete news archive for Urotronic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Urotronic
Urotronic was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Urotronic is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
David Perry is the current CEO of Urotronic.
Urotronic is a funded company, having raised a total of $47.05M across 4 funding rounds to date.
Urotronic was founded in 2015 and is based in Plymouth, United States. Operations center on the medical device sector, specifically urological applications. A urethral device known as the Optilume drug-coated balloon has been created for stricture treatment. Balloon dilation is combined with drug delivery technology, where paclitaxel uptake is employed to restrict cell proliferation and fibrotic scar tissue formation, addressing recurrence issues.
Urotronic offers Optilume BPH Catheter System, Optilume Urethral Drug Coated Balloon, alpHaONE Wireless pH Capsule, and NXT Family of Urodynamics Systems.
Urotronic has 4 investors. Key investors include Laborie Medical, Legend Capital, CD Capital, and HM Venture Partners.